Overview

Early Treatment Strategy With High-dose Dexamethasone in Patients With SARS-CoV-2

Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Early identification and treatment of this inflammatory cascade using existing therapeutic strategies with proven safety profiles could change the course and prognosis of COVID-19 infection, reducing mortality rates. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death
Phase:
Phase 3
Details
Lead Sponsor:
Hospital Universitario Infanta Leonor
Treatments:
Dexamethasone